See more : Fynske Bank A/S (FYNBK.CO) Income Statement Analysis – Financial Results
Complete financial analysis of Microbix Biosystems Inc. (MBXBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Microbix Biosystems Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bafna Pharmaceuticals Limited (BAFNAPHARM.BO) Income Statement Analysis – Financial Results
- Formosa Advanced Technologies Co., Ltd. (8131.TW) Income Statement Analysis – Financial Results
- Goodfood Market Corp. (FOOD.TO) Income Statement Analysis – Financial Results
- The Hydration Pharmaceuticals Company Limited (HPC.AX) Income Statement Analysis – Financial Results
- Eurobank Ergasias Services and Holdings S.A. (EGFEF) Income Statement Analysis – Financial Results
Microbix Biosystems Inc. (MBXBF)
About Microbix Biosystems Inc.
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. It manufactures a range of critical biological materials for the diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment and proficiency (QAPs) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows. The company also applies its biological expertise and infrastructure to develop other proprietary products, primarily viral transport medium (DxTM) to stabilize patient samples for lab-based testing and Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots. It sells QAPs to lab accreditation organizations, diagnostics companies, and clinical labs through a network of regional distributors. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25.39M | 16.51M | 19.08M | 18.59M | 10.52M | 13.41M | 12.51M | 10.19M | 9.52M | 8.87M | 8.40M | 7.57M | 6.67M | 6.23M | 6.46M | 6.08M | 4.99M | 4.05M | 3.64M | 4.38M | 4.07M | 2.85M | 2.81M | 2.99M | 1.86M | 1.60M | 3.10M | 2.70M |
| Cost of Revenue | 10.00M | 9.03M | 7.95M | 7.55M | 5.86M | 6.86M | 7.14M | 5.37M | 4.54M | 3.03M | 3.89M | 3.74M | 3.91M | 3.24M | 2.73M | 2.52M | 2.48M | 2.12M | 1.75M | 1.68M | 1.49M | 1.02M | 835.27K | 949.84K | 577.27K | 600.00K | 600.00K | 500.00K |
| Gross Profit | 15.39M | 7.48M | 11.12M | 11.04M | 4.66M | 6.55M | 5.37M | 4.81M | 4.98M | 5.84M | 4.51M | 3.83M | 2.75M | 2.98M | 3.73M | 3.56M | 2.51M | 1.93M | 1.89M | 2.70M | 2.58M | 1.82M | 1.97M | 2.04M | 1.28M | 1.00M | 2.50M | 2.20M |
| Gross Profit Ratio | 60.61% | 45.30% | 58.32% | 59.40% | 44.28% | 48.82% | 42.92% | 47.25% | 52.33% | 65.81% | 53.73% | 50.62% | 41.30% | 47.92% | 57.78% | 58.60% | 50.36% | 47.74% | 51.94% | 61.72% | 63.36% | 64.03% | 70.24% | 68.22% | 68.91% | 62.50% | 80.65% | 81.48% |
| Research & Development | 2.13M | 2.05M | 1.80M | 1.03M | 1.01M | 1.04M | 1.09M | 994.58K | 493.61K | 1.28M | 691.07K | 445.82K | 560.00K | 530.07K | 494.25K | 703.06K | 1.19M | 985.42K | 886.05K | 572.87K | 966.80K | 668.39K | 443.78K | 346.67K | 228.62K | 3.80M | 1.60M | 900.00K |
| General & Administrative | 8.63M | 6.53M | 5.00M | 4.22M | 3.54M | 3.74M | 3.61M | 3.93M | 3.13M | 2.87M | 1.85M | 1.79M | 2.25M | 2.24M | 2.96M | 2.89M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 246.68K | 1.48M | 1.55M | 858.06K | 632.55K | 651.46K | 556.41K | 464.91K | 517.02K | 602.23K | 656.99K | 893.58K | 1.52M | 1.39M | 1.47M | 1.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.88M | 8.01M | 6.56M | 5.07M | 4.17M | 4.40M | 4.17M | 4.39M | 3.65M | 3.47M | 2.50M | 2.68M | 3.77M | 3.64M | 4.43M | 4.35M | 4.46M | 3.02M | 2.68M | 1.81M | 1.51M | 1.43M | 1.26M | 1.20M | 1.24M | 1.50M | 2.60M | 1.20M |
| Other Expenses | 482.14K | 161.24K | 160.34K | 99.40K | 0.00 | 0.00 | 0.00 | -273.54K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 11.49M | 10.22M | 8.51M | 6.21M | 5.19M | 5.44M | 5.26M | 5.39M | 4.14M | 4.75M | 3.19M | 3.09M | 4.33M | 4.63M | 5.39M | 5.93M | 6.00M | 4.27M | 3.81M | 2.55M | 2.63M | 2.25M | 1.86M | 1.73M | 1.67M | 5.60M | 4.50M | 2.30M |
| Cost & Expenses | 21.49M | 19.25M | 16.47M | 13.76M | 11.05M | 12.30M | 12.40M | 10.76M | 8.68M | 7.78M | 7.08M | 6.83M | 8.25M | 7.87M | 8.11M | 8.45M | 8.48M | 6.39M | 5.56M | 4.23M | 4.12M | 3.27M | 2.70M | 2.68M | 2.25M | 6.20M | 5.10M | 2.80M |
| Interest Income | 687.51K | 457.74K | 82.27K | 66.00 | 1.06M | 1.07M | 172.00 | 22.00 | 616.00 | 2.79K | 9.81K | 9.16K | 159.00 | 3.50K | 2.00K | 46.14K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 921.78K | 839.38K | 826.56K | 1.60M | 1.06M | 1.07M | 852.03K | 924.61K | 691.25K | 745.22K | 850.88K | 718.78K | 1.06M | 976.03K | 889.68K | 161.59K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.61M | 1.16M | 1.04M | 822.04K | 690.09K | 568.82K | 690.08K | 510.16K | 413.68K | 418.42K | 403.26K | 419.20K | 431.23K | 460.76K | 457.09K | 410.49K | 355.71K | 273.39K | 242.64K | 166.59K | 154.08K | 153.92K | 160.52K | 180.25K | 207.36K | 300.00K | 300.00K | 200.00K |
| EBITDA | 6.21M | 1.96M | 3.33M | 5.39M | -95.44K | 1.54M | -7.08M | -2.80M | 1.25M | 1.51M | 1.73M | 1.31M | -1.25M | -1.08M | -1.19M | -1.31M | -3.13M | -2.07M | -1.68M | 317.60K | 101.14K | -272.42K | 266.86K | 493.44K | -186.30K | -4.40M | -1.90M | 100.00K |
| EBITDA Ratio | 24.44% | 11.85% | 19.55% | 30.43% | 1.57% | 12.52% | 6.39% | -3.32% | 13.17% | 17.05% | 20.60% | 15.51% | -17.17% | -18.90% | -18.47% | -21.60% | -62.77% | -51.07% | -45.97% | 7.26% | 2.49% | -9.57% | 9.51% | 16.51% | -10.03% | -268.75% | -54.84% | 3.70% |
| Operating Income | 3.91M | -2.74M | 2.69M | 4.84M | -524.60K | 1.11M | -742.81K | -1.50M | 148.41K | 348.98K | 475.62K | 168.18K | -1.58M | -1.64M | -1.65M | -1.72M | -3.49M | -2.34M | -1.92M | 151.02K | -52.95K | -426.33K | 106.34K | 313.18K | -393.66K | -4.60M | -2.00M | -100.00K |
| Operating Income Ratio | 15.38% | -16.57% | 14.11% | 26.01% | -4.98% | 8.27% | -5.94% | -14.72% | 1.56% | 3.93% | 5.66% | 2.22% | -23.63% | -26.35% | -25.54% | -28.35% | -69.89% | -57.83% | -52.63% | 3.45% | -1.30% | -14.98% | 3.79% | 10.48% | -21.20% | -287.50% | -64.52% | -3.70% |
| Total Other Income/Expenses | -234.27K | 2.70M | -744.29K | -1.60M | -4.13M | -1.07M | -7.88M | -2.73M | -689.61K | -742.44K | -752.12K | 311.81K | -812.73K | -1.02M | -887.68K | 0.00 | 0.00 | -370.57K | -174.11K | 62.51K | 153.76K | 112.50K | 18.57K | 31.16K | 20.08K | 0.00 | 100.00K | 100.00K |
| Income Before Tax | 3.67M | -39.48K | 1.87M | 3.23M | -4.66M | 43.68K | -8.62M | -4.23M | 148.41K | 348.98K | 475.62K | 168.18K | -2.64M | -2.61M | -2.54M | 0.00 | 0.00 | -2.71M | -2.09M | 213.53K | 97.06K | -313.83K | 124.91K | 344.35K | -373.58K | 0.00 | -1.90M | 0.00 |
| Income Before Tax Ratio | 14.46% | -0.24% | 9.78% | 17.39% | -44.27% | 0.33% | -68.91% | -41.53% | 1.56% | 3.93% | 5.66% | 2.22% | -39.53% | -41.97% | -39.28% | 0.00% | 0.00% | -66.98% | -57.41% | 4.88% | 2.39% | -11.02% | 4.45% | 11.52% | -20.12% | 0.00% | -61.29% | 0.00% |
| Income Tax Expense | 150.56K | 0.00 | 77.23K | 1.60M | 1.57M | 11.76K | 852.03K | -450.00K | -600.00K | -265.00K | 306.65K | 166.80K | 159.00 | 3.50K | 887.68K | 759.98K | 177.83K | 0.00 | 211.61K | 88.00K | 82.79K | 49.88K | 55.40K | 103.23K | 76.65K | 100.00K | 200.00K | 100.00K |
| Net Income | 3.52M | -39.48K | 1.79M | 1.63M | -6.23M | 31.92K | -8.62M | -3.78M | 748.41K | 613.98K | 168.98K | 1.38K | -2.64M | -2.61M | -2.54M | -2.48M | -3.67M | -2.71M | -2.09M | 125.53K | 14.27K | -363.71K | 69.51K | 241.12K | -450.23K | -4.70M | -2.10M | -100.00K |
| Net Income Ratio | 13.86% | -0.24% | 9.38% | 8.77% | -59.17% | 0.24% | -68.91% | -37.11% | 7.86% | 6.92% | 2.01% | 0.02% | -39.53% | -41.97% | -39.28% | -40.85% | -73.45% | -66.98% | -57.41% | 2.87% | 0.35% | -12.78% | 2.48% | 8.07% | -24.25% | -293.75% | -67.74% | -3.70% |
| EPS | 0.00 | 0.00 | 0.01 | 0.01 | -0.06 | 0.00 | -0.09 | -0.04 | 0.01 | 0.01 | 0.00 | 0.00 | -0.04 | -0.05 | -0.05 | -0.05 | -0.08 | -0.07 | -0.06 | 0.00 | 0.00 | -0.01 | 0.00 | 0.01 | -0.01 | -0.14 | -0.06 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.01 | 0.01 | -0.06 | 0.00 | -0.09 | -0.04 | 0.01 | 0.01 | 0.00 | 0.00 | -0.04 | -0.05 | -0.05 | -0.05 | -0.08 | -0.07 | -0.06 | 0.00 | 0.00 | -0.01 | 0.00 | 0.01 | -0.01 | -0.14 | -0.06 | 0.00 |
| Weighted Avg Shares Out | 0.00 | 138.05M | 135.38M | 114.85M | 104.84M | 96.97M | 95.80M | 84.70M | 84.66M | 80.87M | 68.98M | 66.60M | 61.93M | 54.84M | 48.63M | 46.45M | 45.85M | 38.74M | 34.87M | 34.91M | 34.50M | 36.37M | 34.48M | 34.48M | 34.37M | 33.57M | 35.00M | 32.32M |
| Weighted Avg Shares Out (Dil) | 0.00 | 137.91M | 141.69M | 141.68M | 104.84M | 97.09M | 96.20M | 84.70M | 84.71M | 82.15M | 72.23M | 66.60M | 61.93M | 54.84M | 48.63M | 46.45M | 45.85M | 38.74M | 34.87M | 34.91M | 34.50M | 36.37M | 34.48M | 34.48M | 34.37M | 33.57M | 35.00M | 32.32M |
Microbix QAPs Supporting HPV Testing in Ireland
Distribution Partner Secures Contract Relating to Cervical Cancer Screening Distribution Partner Secures Contract Relating to Cervical Cancer Screening
Microbix Presenting at Muskoka Capital Conference
Meetings with Growth-Oriented Investors, September 29 to October 1, 2023 Meetings with Growth-Oriented Investors, September 29 to October 1, 2023
Microbix Honours the Passing of its Founder
MISSISSAUGA, Ontario, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, honours the passing of its founder, William J.
Microbix Biosystems Inc. (MBXBF) Q3 2023 Earnings Call Transcript
Microbix Biosystems Inc. (OTCQX:MBXBF) Q3 2023 Results Conference Call August 14, 2023 11:00 AM ET Company Participants Deborah Honig - Investor Relations Cameron Groome - Chief Executive Officer and President Kenneth Hughes - Chief Operating Officer James Currie - Chief...
Microbix Reports Results for Q3 Fiscal 2023
MISSISSAUGA, Ontario, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and YTD fiscal 2023 ended June 30, 2023 (“Q3” and...
Microbix Successfully Upgrades Logistics Software Systems Achieves “Go-Live” with New ERP and eQMS Solutions
MISSISSAUGA, Ontario, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces its successful adoption of software to upgrade, digitize, and integrate its Enterprise Resource Planning (“ERP”)...
Microbix Presents Results of STI Test Controls at AACC
FLOQSwab-formatted QAPs Supporting Fourplex PCR Tests for Bacterial STIs FLOQSwab-formatted QAPs Supporting Fourplex PCR Tests for Bacterial STIs
Microbix Biosystems Inc. (MBXBF) Q1 2023 Earnings Call Transcript
Microbix Biosystems Inc. (OTCQX:MBXBF) Q1 2023 Earnings Conference Call February 14, 2023 11:00 AM ET Company Participants Deborah Honig - Investor Relations, Adelaide Capital Cameron Groome - Chief Executive Officer Jim Currie - Chief Financial Officer Ken Hughes - Chief...
Microbix Biosystems Inc. (MBXBF) Q4 2022 Earnings Call Transcript
Microbix Biosystems Inc. (OTCQX:MBXBF) Q4 2022 Earnings Conference Call January 4, 2023 11:00 AM ET Company Participants Deborah Honig - IR, Adelaide Capital Cameron Groome - President and CEO Jim Currie - CFO Ken Hughes - COO Deborah Honig Thanks...
Microbix Biosystems Inc. (MBXBF) CEO Cameron Groome on Q3 2022 Results - Earnings Call Transcript
Microbix Biosystems Inc. (OTCQX:MBXBF) Q3 2022 Earnings Conference Call August 17, 2022 11:00 AM ET Company Participants Cameron Groome - President and CEO Jim Currie - CFO Ken Hughes - COO Conference Call Participants Deborah Honig - IR, Adelaide Capital...
Source: https://incomestatements.info
Category: Stock Reports